HLB Therapeutics Co.,Ltd. Logo

HLB Therapeutics Co.,Ltd.

Develops innovative drugs for rare eye diseases and brain tumors, with vaccine logistics.

115450 | KO

Overview

Corporate Details

ISIN(s):
KR7115450009
LEI:
Country:
South Korea
Address:
경기도 성남시 분당구 정자일로 248, 성남시
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

HLB Therapeutics Co., Ltd. is a biopharmaceutical company specializing in the development of innovative, first-in-class drugs for rare and intractable diseases. The company's core focus is on its clinical pipeline, which includes RGN-259, a therapeutic candidate for ophthalmic conditions such as Neurotrophic Keratopathy and Dry Eye Disease, and OKN-007 for treating Glioblastoma Multiforme. In addition to its primary research and development activities, the company has diversified business areas that include vaccine distribution and cold chain logistics.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-28 00:00
Share Issue/Capital Change
전환가액의조정
Korean 10.6 KB
2025-08-28 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 25.1 KB
2025-08-28 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 137.3 KB
2025-08-21 00:00
Share Issue/Capital Change
전환가액의조정
Korean 11.8 KB
2025-08-21 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 137.5 KB
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 1.8 MB
2025-07-10 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 136.8 KB
2025-07-04 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 141.7 KB
2025-07-03 00:00
Share Issue/Capital Change
증권발행결과(자율공시)
Korean 5.6 KB
2025-07-01 00:00
Share Issue/Capital Change
전환가액의조정
Korean 13.1 KB
2025-06-20 00:00
Capital/Financing Update
주요사항보고서(전환사채권발행결정)
Korean 73.7 KB
2025-05-28 00:00
Share Issue/Capital Change
전환가액의조정 (제18회차)
Korean 10.2 KB
2025-05-28 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 25.1 KB
2025-05-28 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 119.0 KB
2025-05-21 00:00
Share Issue/Capital Change
전환가액의조정 (제17회차)
Korean 11.3 KB

Automate Your Workflow. Get a real-time feed of all HLB Therapeutics Co.,Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for HLB Therapeutics Co.,Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for HLB Therapeutics Co.,Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

VALIRX PLC Logo
Advancing oncology & women's health therapeutics and offering preclinical research services.
United Kingdom
VAL
VALUE GOLF Inc. Logo
A golf services hub offering reservations, solo player bookings, e-commerce, lessons, and tours.
Japan
3931
Value HR Co., Ltd. Logo
Offers a health management platform and consulting for corporate health insurance societies in Japan.
Japan
6078
Global OTA for curated tours & experiences, focusing on travel to and from Japan.
Japan
7048
A South Korean travel company offering global tour packages, flights, hotels, and corporate travel.
South Korea
094850
Virax Biolabs Group Ltd Logo
Specializes in T-cell immunity tests and diagnostics for profiling viral disease responses.
United States of America
VRAX
VisionSys AI Inc Logo
Develops AI-powered brain-computer interfaces for the healthcare and biotech sectors.
United States of America
VSA
Vivesto Logo
Develops and licenses novel cancer therapies for humans and animals using proprietary drug delivery.
Sweden
VIVE
Vor Biopharma Inc. Logo
Clinical-stage biotech developing next-gen medicines that target the root cause of autoimmune disease.
United States of America
VOR
Voronoi, Inc. Logo
Develops selective kinase inhibitors and targeted protein degraders for precision oncology.
South Korea
310210

Talk to a Data Expert

Have a question? We'll get back to you promptly.